| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 50 | 2024 | 636 | 11.620 |
Why?
|
| Rituximab | 47 | 2023 | 1593 | 4.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 77 | 2023 | 16669 | 3.170 |
Why?
|
| Lymphoma, Non-Hodgkin | 17 | 2021 | 1067 | 2.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 30 | 2024 | 1738 | 2.560 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 15 | 2023 | 331 | 2.190 |
Why?
|
| Lymphoma, B-Cell | 16 | 2023 | 929 | 2.180 |
Why?
|
| Lymphoma, Mantle-Cell | 15 | 2023 | 749 | 2.140 |
Why?
|
| Lymphoma | 14 | 2021 | 1520 | 1.790 |
Why?
|
| Adenine | 16 | 2023 | 672 | 1.630 |
Why?
|
| Piperidines | 17 | 2023 | 1098 | 1.520 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 1135 | 1.440 |
Why?
|
| Thalidomide | 9 | 2018 | 595 | 1.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 | 2021 | 2484 | 1.150 |
Why?
|
| Bendamustine Hydrochloride | 7 | 2020 | 122 | 1.110 |
Why?
|
| Neoplasm Recurrence, Local | 22 | 2024 | 10385 | 1.090 |
Why?
|
| Salvage Therapy | 12 | 2018 | 2122 | 1.010 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 3 | 2021 | 126 | 1.000 |
Why?
|
| Immunotherapy | 9 | 2024 | 3557 | 1.000 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 8 | 2019 | 192 | 0.990 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 16 | 2020 | 878 | 0.970 |
Why?
|
| Hodgkin Disease | 11 | 2019 | 1485 | 0.950 |
Why?
|
| Antibodies, Monoclonal | 13 | 2020 | 4480 | 0.920 |
Why?
|
| Leukemia, B-Cell | 2 | 2016 | 114 | 0.900 |
Why?
|
| Humans | 177 | 2024 | 270744 | 0.890 |
Why?
|
| Pyrazoles | 10 | 2019 | 1544 | 0.880 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2021 | 5403 | 0.860 |
Why?
|
| Tumor Microenvironment | 11 | 2024 | 3031 | 0.840 |
Why?
|
| Adult | 93 | 2024 | 81975 | 0.840 |
Why?
|
| Radioimmunotherapy | 4 | 2020 | 128 | 0.840 |
Why?
|
| Immunotherapy, Adoptive | 8 | 2024 | 1840 | 0.810 |
Why?
|
| Standard of Care | 1 | 2024 | 277 | 0.810 |
Why?
|
| Intraocular Lymphoma | 3 | 2016 | 15 | 0.790 |
Why?
|
| Central Nervous System Neoplasms | 6 | 2021 | 551 | 0.780 |
Why?
|
| Middle Aged | 101 | 2024 | 90334 | 0.770 |
Why?
|
| Aged | 92 | 2024 | 73375 | 0.760 |
Why?
|
| Biological Products | 3 | 2024 | 319 | 0.760 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 2 | 2017 | 15 | 0.710 |
Why?
|
| Vincristine | 18 | 2022 | 1582 | 0.700 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2021 | 1267 | 0.700 |
Why?
|
| Antineoplastic Agents | 19 | 2021 | 14616 | 0.690 |
Why?
|
| Pyrimidines | 11 | 2019 | 3667 | 0.690 |
Why?
|
| Male | 102 | 2024 | 128374 | 0.670 |
Why?
|
| Quinazolinones | 2 | 2016 | 52 | 0.660 |
Why?
|
| Mitoxantrone | 2 | 2017 | 227 | 0.650 |
Why?
|
| Treatment Outcome | 50 | 2024 | 33733 | 0.620 |
Why?
|
| Exanthema | 2 | 2023 | 212 | 0.620 |
Why?
|
| Female | 101 | 2024 | 148945 | 0.620 |
Why?
|
| Lymphoma, T-Cell | 3 | 2019 | 366 | 0.610 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2023 | 4961 | 0.600 |
Why?
|
| Neoplasm Staging | 29 | 2019 | 14012 | 0.600 |
Why?
|
| Receptors, Antigen, B-Cell | 3 | 2015 | 174 | 0.590 |
Why?
|
| Purines | 2 | 2016 | 271 | 0.590 |
Why?
|
| Aged, 80 and over | 52 | 2021 | 31006 | 0.580 |
Why?
|
| Safety | 1 | 2019 | 461 | 0.570 |
Why?
|
| Nitrogen Mustard Compounds | 2 | 2015 | 74 | 0.570 |
Why?
|
| Prednisone | 14 | 2020 | 1033 | 0.570 |
Why?
|
| Immunologic Factors | 2 | 2020 | 672 | 0.560 |
Why?
|
| Oncology Nursing | 1 | 2017 | 54 | 0.550 |
Why?
|
| Hematologic Diseases | 4 | 2015 | 255 | 0.550 |
Why?
|
| Doxorubicin | 18 | 2022 | 3145 | 0.510 |
Why?
|
| B-Lymphocytes | 5 | 2024 | 1424 | 0.510 |
Why?
|
| Neoplasm Proteins | 5 | 2020 | 3346 | 0.510 |
Why?
|
| Interferons | 1 | 2017 | 299 | 0.510 |
Why?
|
| Cyclophosphamide | 18 | 2022 | 3243 | 0.510 |
Why?
|
| Follow-Up Studies | 26 | 2024 | 15210 | 0.500 |
Why?
|
| Mycosis Fungoides | 1 | 2018 | 341 | 0.500 |
Why?
|
| Antigens, CD19 | 6 | 2024 | 584 | 0.490 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 625 | 0.490 |
Why?
|
| Molecular Targeted Therapy | 7 | 2016 | 2399 | 0.480 |
Why?
|
| Lymphocytes | 2 | 2019 | 1275 | 0.480 |
Why?
|
| Remission Induction | 10 | 2019 | 3652 | 0.470 |
Why?
|
| Meningeal Neoplasms | 2 | 2018 | 473 | 0.450 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 322 | 0.440 |
Why?
|
| Communicable Diseases | 1 | 2015 | 208 | 0.430 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 60 | 0.410 |
Why?
|
| Recurrence | 17 | 2024 | 4875 | 0.400 |
Why?
|
| Disease-Free Survival | 21 | 2020 | 10260 | 0.390 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2023 | 1838 | 0.380 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2022 | 3408 | 0.380 |
Why?
|
| Combined Modality Therapy | 17 | 2019 | 9039 | 0.370 |
Why?
|
| Survival Rate | 21 | 2022 | 12526 | 0.370 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2021 | 1013 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 9041 | 0.360 |
Why?
|
| Young Adult | 34 | 2019 | 22216 | 0.350 |
Why?
|
| Positron-Emission Tomography | 7 | 2020 | 2196 | 0.340 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2020 | 6255 | 0.340 |
Why?
|
| Skin Neoplasms | 5 | 2021 | 4889 | 0.320 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2022 | 381 | 0.320 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 1946 | 0.320 |
Why?
|
| Protein Kinases | 1 | 2013 | 903 | 0.310 |
Why?
|
| Radiotherapy | 6 | 2017 | 1857 | 0.310 |
Why?
|
| Orbital Neoplasms | 3 | 2020 | 233 | 0.300 |
Why?
|
| Stomach Neoplasms | 6 | 2020 | 2330 | 0.300 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 66 | 0.300 |
Why?
|
| Sulfonamides | 4 | 2021 | 1933 | 0.290 |
Why?
|
| Mutation | 10 | 2022 | 15911 | 0.290 |
Why?
|
| Maintenance Chemotherapy | 3 | 2018 | 224 | 0.290 |
Why?
|
| Prognosis | 23 | 2024 | 22480 | 0.290 |
Why?
|
| Mediastinal Neoplasms | 3 | 2016 | 427 | 0.290 |
Why?
|
| Retrospective Studies | 31 | 2022 | 39827 | 0.270 |
Why?
|
| Oligonucleotides | 2 | 2018 | 242 | 0.270 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2018 | 255 | 0.260 |
Why?
|
| Transcriptome | 5 | 2024 | 1960 | 0.260 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2019 | 2161 | 0.260 |
Why?
|
| Biopsy | 9 | 2019 | 3483 | 0.250 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2019 | 1097 | 0.250 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 4958 | 0.250 |
Why?
|
| Signal Transduction | 7 | 2016 | 12102 | 0.250 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1955 | 0.250 |
Why?
|
| Disease Progression | 13 | 2021 | 6855 | 0.250 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 5149 | 0.240 |
Why?
|
| Methotrexate | 6 | 2022 | 1025 | 0.240 |
Why?
|
| Survival Analysis | 11 | 2021 | 9290 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2021 | 1710 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 5 | 2019 | 1320 | 0.230 |
Why?
|
| Neoplasm Grading | 6 | 2021 | 1822 | 0.230 |
Why?
|
| Stem Cell Transplantation | 5 | 2019 | 1414 | 0.230 |
Why?
|
| Neutropenia | 4 | 2021 | 1006 | 0.230 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 1379 | 0.220 |
Why?
|
| Bone Marrow | 6 | 2023 | 2438 | 0.220 |
Why?
|
| Biomarkers, Tumor | 9 | 2024 | 10706 | 0.220 |
Why?
|
| Tumor Escape | 2 | 2016 | 247 | 0.210 |
Why?
|
| Adolescent | 20 | 2019 | 32735 | 0.210 |
Why?
|
| Databases, Factual | 2 | 2021 | 2251 | 0.210 |
Why?
|
| Neoplasms | 4 | 2024 | 15919 | 0.210 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 232 | 0.210 |
Why?
|
| Dexamethasone | 6 | 2018 | 1507 | 0.210 |
Why?
|
| Yttrium Radioisotopes | 3 | 2020 | 210 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2019 | 5070 | 0.210 |
Why?
|
| Hepacivirus | 2 | 2015 | 423 | 0.200 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2020 | 125 | 0.200 |
Why?
|
| Testicular Neoplasms | 3 | 2018 | 560 | 0.200 |
Why?
|
| Radiation Injuries | 4 | 2020 | 1470 | 0.200 |
Why?
|
| Pyrazines | 2 | 2017 | 510 | 0.190 |
Why?
|
| Depsipeptides | 2 | 2019 | 77 | 0.190 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2019 | 1260 | 0.190 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 25 | 0.190 |
Why?
|
| Proteogenomics | 1 | 2022 | 109 | 0.190 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 3530 | 0.190 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 3845 | 0.190 |
Why?
|
| Thrombocytopenia | 3 | 2022 | 870 | 0.180 |
Why?
|
| Hydroxamic Acids | 2 | 2013 | 454 | 0.180 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2020 | 15 | 0.180 |
Why?
|
| Cytarabine | 5 | 2022 | 2013 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1335 | 0.170 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2020 | 49 | 0.170 |
Why?
|
| Induction Chemotherapy | 3 | 2019 | 670 | 0.170 |
Why?
|
| Hepatitis C | 2 | 2015 | 549 | 0.170 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2021 | 116 | 0.170 |
Why?
|
| Lymphopenia | 1 | 2022 | 211 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2018 | 1717 | 0.170 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2022 | 7017 | 0.170 |
Why?
|
| Immunophenotyping | 3 | 2022 | 1726 | 0.170 |
Why?
|
| Burkitt Lymphoma | 1 | 2022 | 348 | 0.160 |
Why?
|
| Drug Resistance | 2 | 2018 | 610 | 0.160 |
Why?
|
| RNA | 1 | 2024 | 1064 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2019 | 880 | 0.160 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2018 | 33 | 0.150 |
Why?
|
| beta 2-Microglobulin | 2 | 2016 | 189 | 0.150 |
Why?
|
| Drug Substitution | 2 | 2015 | 87 | 0.150 |
Why?
|
| Etoposide | 5 | 2018 | 907 | 0.150 |
Why?
|
| Bortezomib | 3 | 2018 | 543 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 599 | 0.140 |
Why?
|
| Education, Nursing, Continuing | 1 | 2017 | 25 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3656 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Germinal Center | 1 | 2017 | 167 | 0.140 |
Why?
|
| Biomarkers | 6 | 2019 | 5060 | 0.140 |
Why?
|
| Gene Rearrangement | 1 | 2020 | 813 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2020 | 1542 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2019 | 562 | 0.130 |
Why?
|
| Castleman Disease | 1 | 2016 | 71 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2019 | 1609 | 0.130 |
Why?
|
| Prospective Studies | 9 | 2024 | 13414 | 0.130 |
Why?
|
| Procarbazine | 1 | 2015 | 71 | 0.130 |
Why?
|
| Melphalan | 1 | 2019 | 875 | 0.130 |
Why?
|
| Conjunctival Neoplasms | 1 | 2017 | 124 | 0.130 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 617 | 0.130 |
Why?
|
| B-Cell Activation Factor Receptor | 1 | 2015 | 26 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2017 | 256 | 0.130 |
Why?
|
| Chemokine CCL4 | 1 | 2015 | 68 | 0.130 |
Why?
|
| Vidarabine | 2 | 2019 | 1383 | 0.130 |
Why?
|
| Chemokine CCL3 | 1 | 2015 | 65 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 1077 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 7894 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 246 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2016 | 107 | 0.120 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 460 | 0.120 |
Why?
|
| Resorcinols | 1 | 2015 | 27 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 2846 | 0.120 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 660 | 0.120 |
Why?
|
| Viremia | 1 | 2015 | 182 | 0.120 |
Why?
|
| Sequence Analysis, RNA | 3 | 2024 | 676 | 0.120 |
Why?
|
| Leukocyte Count | 1 | 2016 | 735 | 0.120 |
Why?
|
| Eye Diseases | 1 | 2016 | 129 | 0.120 |
Why?
|
| Isoxazoles | 1 | 2015 | 81 | 0.120 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 257 | 0.120 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 153 | 0.120 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 235 | 0.120 |
Why?
|
| Time Factors | 11 | 2021 | 13021 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2019 | 815 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2016 | 329 | 0.120 |
Why?
|
| Radiotherapy Dosage | 6 | 2020 | 4001 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1387 | 0.110 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 191 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 690 | 0.110 |
Why?
|
| Congenital Abnormalities | 1 | 2016 | 280 | 0.110 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 5102 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2021 | 1208 | 0.110 |
Why?
|
| Receptor Cross-Talk | 1 | 2013 | 79 | 0.110 |
Why?
|
| Hospitalization | 1 | 2022 | 2168 | 0.110 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 313 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 1136 | 0.110 |
Why?
|
| Helicobacter pylori | 2 | 2020 | 1434 | 0.100 |
Why?
|
| Immunoconjugates | 1 | 2016 | 314 | 0.100 |
Why?
|
| Monocytes | 1 | 2016 | 790 | 0.100 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2013 | 219 | 0.100 |
Why?
|
| Bone Resorption | 1 | 2012 | 136 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 168 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2019 | 2073 | 0.100 |
Why?
|
| Spinal Cord | 1 | 2015 | 720 | 0.100 |
Why?
|
| Benzamides | 1 | 2017 | 1879 | 0.100 |
Why?
|
| Neutrophils | 1 | 2016 | 873 | 0.100 |
Why?
|
| Urate Oxidase | 1 | 2011 | 43 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 2651 | 0.100 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2011 | 40 | 0.100 |
Why?
|
| Proteasome Inhibitors | 1 | 2013 | 232 | 0.100 |
Why?
|
| Conjunctiva | 1 | 2013 | 225 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 2062 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2022 | 3108 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 205 | 0.090 |
Why?
|
| Electrocardiography | 7 | 1983 | 1155 | 0.090 |
Why?
|
| Gout Suppressants | 1 | 2011 | 72 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2012 | 264 | 0.090 |
Why?
|
| Drug Design | 1 | 2013 | 371 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2023 | 1655 | 0.090 |
Why?
|
| Algorithms | 2 | 2022 | 3900 | 0.090 |
Why?
|
| Plasmacytoma | 1 | 2011 | 122 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 2388 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 622 | 0.090 |
Why?
|
| Machine Learning | 2 | 2024 | 363 | 0.090 |
Why?
|
| Arrhythmias, Cardiac | 4 | 1976 | 506 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2011 | 354 | 0.080 |
Why?
|
| Incidence | 5 | 2019 | 5825 | 0.080 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2013 | 1564 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 3176 | 0.080 |
Why?
|
| Sirolimus | 1 | 2013 | 831 | 0.080 |
Why?
|
| Central Nervous System | 2 | 2022 | 453 | 0.080 |
Why?
|
| Autografts | 2 | 2020 | 179 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 637 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 2 | 2015 | 471 | 0.080 |
Why?
|
| Indoles | 1 | 2013 | 1028 | 0.080 |
Why?
|
| Risk Factors | 5 | 2018 | 17896 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 2808 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2022 | 593 | 0.070 |
Why?
|
| Disease Management | 3 | 2019 | 1089 | 0.070 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 557 | 0.070 |
Why?
|
| Ifosfamide | 2 | 2018 | 358 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2394 | 0.070 |
Why?
|
| Imidazoles | 1 | 2012 | 1064 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2154 | 0.070 |
Why?
|
| RNA, Viral | 1 | 2009 | 730 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2015 | 3944 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 2021 | 909 | 0.060 |
Why?
|
| Diarrhea | 2 | 2022 | 716 | 0.060 |
Why?
|
| Cytokines | 3 | 2022 | 2826 | 0.060 |
Why?
|
| DNA | 1 | 2013 | 3051 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2664 | 0.060 |
Why?
|
| Carboplatin | 2 | 2018 | 880 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2019 | 9473 | 0.060 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 2045 | 0.060 |
Why?
|
| Lung | 1 | 2015 | 3300 | 0.060 |
Why?
|
| Melanoma | 1 | 2021 | 5594 | 0.060 |
Why?
|
| Tissue Fixation | 1 | 2024 | 137 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2024 | 3045 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2018 | 1428 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2012 | 2368 | 0.050 |
Why?
|
| Quinidine | 2 | 1973 | 13 | 0.050 |
Why?
|
| Myocardial Infarction | 4 | 1983 | 1180 | 0.050 |
Why?
|
| Multimodal Imaging | 2 | 2017 | 550 | 0.050 |
Why?
|
| Placebos | 3 | 2019 | 443 | 0.050 |
Why?
|
| Guanylate Cyclase | 1 | 2021 | 78 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2015 | 316 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 7784 | 0.050 |
Why?
|
| United States | 4 | 2019 | 15853 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 5231 | 0.050 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2021 | 109 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 1525 | 0.050 |
Why?
|
| Polyethylene Glycols | 2 | 2015 | 654 | 0.050 |
Why?
|
| Brain | 1 | 2014 | 4212 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2022 | 338 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 1752 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 1884 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 2033 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2023 | 1180 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 139 | 0.040 |
Why?
|
| Age Factors | 2 | 2021 | 5465 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 4328 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2021 | 1075 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 121 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2019 | 3078 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 134 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5569 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2021 | 668 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 485 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 7665 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2022 | 6768 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2020 | 450 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 31 | 0.040 |
Why?
|
| Animals | 4 | 2016 | 62045 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 447 | 0.040 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Prevalence | 2 | 2019 | 3401 | 0.030 |
Why?
|
| Allografts | 1 | 2019 | 686 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 307 | 0.030 |
Why?
|
| Chemoradiotherapy | 2 | 2015 | 2027 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2018 | 676 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 179 | 0.030 |
Why?
|
| CD79 Antigens | 1 | 2015 | 7 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2021 | 2308 | 0.030 |
Why?
|
| Orbit | 1 | 2017 | 209 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1352 | 0.030 |
Why?
|
| Abortion, Induced | 1 | 2016 | 94 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 751 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2021 | 1193 | 0.030 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2015 | 35 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 5002 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2018 | 366 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 253 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2016 | 558 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 261 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2015 | 191 | 0.030 |
Why?
|
| Psychotropic Drugs | 1 | 1976 | 140 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 500 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 186 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2014 | 126 | 0.030 |
Why?
|
| Vinblastine | 1 | 2015 | 462 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 156 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Virus Activation | 1 | 2015 | 236 | 0.030 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 172 | 0.030 |
Why?
|
| Bleomycin | 1 | 2015 | 482 | 0.030 |
Why?
|
| Mediastinum | 1 | 2015 | 276 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2013 | 69 | 0.030 |
Why?
|
| Topotecan | 1 | 2014 | 248 | 0.030 |
Why?
|
| Chemokine CCL17 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Chemokine CCL22 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Viral Load | 1 | 2015 | 485 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 262 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 897 | 0.030 |
Why?
|
| Edema | 1 | 2015 | 263 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 1973 | 38 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 271 | 0.030 |
Why?
|
| Coinfection | 1 | 2015 | 200 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2015 | 502 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 12028 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2015 | 337 | 0.030 |
Why?
|
| Genes, myc | 1 | 2014 | 372 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2015 | 601 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4497 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2015 | 1359 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1571 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 730 | 0.020 |
Why?
|
| Texas | 2 | 2015 | 6447 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2015 | 1825 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 610 | 0.020 |
Why?
|
| Everolimus | 1 | 2013 | 436 | 0.020 |
Why?
|
| Uric Acid | 1 | 2011 | 117 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2013 | 374 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 2209 | 0.020 |
Why?
|
| Helicobacter Infections | 1 | 2020 | 1351 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2015 | 2319 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 2455 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 100 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2015 | 7237 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 607 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2016 | 1389 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2015 | 513 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2011 | 376 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2091 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 14838 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1436 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 875 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2012 | 386 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 1973 | 522 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 965 | 0.020 |
Why?
|
| Bone Density | 1 | 2012 | 467 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2016 | 1933 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 1341 | 0.020 |
Why?
|
| Egypt | 1 | 2009 | 45 | 0.020 |
Why?
|
| Research Design | 1 | 2016 | 1569 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 1940 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 2026 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2836 | 0.020 |
Why?
|
| Heart Ventricles | 4 | 1983 | 848 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1973 | 767 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2015 | 1110 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 4048 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3439 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1469 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 5437 | 0.020 |
Why?
|
| Fatigue | 1 | 2015 | 1279 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1285 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 1089 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4374 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 4329 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 693 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 4829 | 0.020 |
Why?
|
| Hemodynamics | 2 | 1983 | 950 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6686 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2392 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2015 | 1253 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 749 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 743 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 3588 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 1046 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 2196 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2474 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 521 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 2101 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3919 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 3642 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 4255 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2020 | 5440 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 3043 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 4140 | 0.020 |
Why?
|
| Child | 2 | 2017 | 30538 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2010 | 2271 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 3089 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 2450 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 5310 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2009 | 2311 | 0.010 |
Why?
|
| Blood Pressure | 3 | 1983 | 1571 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 16205 | 0.010 |
Why?
|
| Acute Disease | 3 | 1973 | 2496 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 8124 | 0.010 |
Why?
|
| Quality of Life | 1 | 2016 | 4775 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 4001 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 3448 | 0.010 |
Why?
|
| Apoptosis | 1 | 2015 | 7754 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 6237 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 4820 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 5921 | 0.010 |
Why?
|
| Digitalis Glycosides | 1 | 1976 | 7 | 0.010 |
Why?
|
| Thioridazine | 1 | 1976 | 5 | 0.010 |
Why?
|
| Mesoridazine | 1 | 1976 | 2 | 0.010 |
Why?
|
| Phenothiazines | 1 | 1976 | 10 | 0.010 |
Why?
|
| Chlorpromazine | 1 | 1976 | 20 | 0.010 |
Why?
|
| Adrenergic Agonists | 1 | 1976 | 14 | 0.010 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1976 | 38 | 0.010 |
Why?
|
| Lidocaine | 1 | 1976 | 82 | 0.010 |
Why?
|
| Diuretics | 1 | 1976 | 171 | 0.010 |
Why?
|
| Cardiovascular System | 1 | 1976 | 142 | 0.010 |
Why?
|
| Hypotension | 1 | 1976 | 231 | 0.010 |
Why?
|
| Methods | 1 | 1973 | 223 | 0.010 |
Why?
|
| Online Systems | 1 | 1973 | 25 | 0.010 |
Why?
|
| Enzymes | 1 | 1973 | 71 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1973 | 452 | 0.010 |
Why?
|
| Heart Conduction System | 1 | 1973 | 161 | 0.010 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 1973 | 160 | 0.010 |
Why?
|
| Heart Atria | 1 | 1973 | 354 | 0.010 |
Why?
|
| Heart Rate | 1 | 1971 | 751 | 0.000 |
Why?
|
| Lung Diseases | 1 | 1970 | 755 | 0.000 |
Why?
|
| Mercury | 1 | 1983 | 32 | 0.000 |
Why?
|
| Bundle-Branch Block | 1 | 1983 | 38 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1983 | 194 | 0.000 |
Why?
|
| Heart Failure | 1 | 1976 | 2333 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1983 | 301 | 0.000 |
Why?
|
| Dogs | 1 | 1983 | 1160 | 0.000 |
Why?
|
| Respiratory Function Tests | 1 | 1970 | 354 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1970 | 1825 | 0.000 |
Why?
|